IRIDEX Announces Approval of CYCLO G6™ Glaucoma Laser System in Korea
June 19 2018 - 8:00AM
IRIDEX Corporation (Nasdaq:IRIX) today announced the approval of
its CYCLO G6™ Glaucoma Laser system by South Korea's Ministry of
Food and Drug Safety (MFDS). Currently available in more than
50 countries, the CYCLO G6 treats patients diagnosed with a range
of glaucoma disease states using the Company’s proprietary
MicroPulse® technology and a family of single use probes.
“International expansion in the Asia-Pacific region remains a
top priority for us and we believe that Korea represents an
attractive market opportunity for our G6 technology,” said William
M. Moore, President and Chief Executive Officer. “We set G6
approval in Korea as a key target for our 2018 expansion strategy
and I am delighted to have reached this key milestone.
Importantly, we have already started to garner feedback and support
from key opinion leaders in the region and expect to leverage their
support in our launch strategy.”
The CYCLO G6 platform is supported by a growing body of clinical
evidence and extensive validation in the field for the treatment of
glaucoma. Physicians worldwide have adopted the G6 because it
is safe, minimally invasive, non-incisional, repeatable and
durable. Moreover, the G6 provides physicians and the
healthcare system a cost-effective solution for the treatment of
glaucoma across the full continuum of care – from early stage to
late stage glaucoma.
"We believe these tangible reasons are driving increased
awareness and excitement in the worldwide glaucoma community for
our G6. We look forward to continued success accelerating CYCLO G6
adoption and utilization,” concluded Moore.
About IRIDEX
IRIDEX Corporation is a worldwide leader in developing,
manufacturing, and marketing innovative and versatile laser-based
medical systems, delivery devices and consumable instrumentation
for the ophthalmology market. The Company’s proprietary MicroPulse®
technology delivers a differentiated treatment that provides safe,
effective, and proven treatment for targeted sight-threatening eye
conditions. IRIDEX’s current product line is used for the treatment
of glaucoma, diabetic macular edema (DME) and other retinal
diseases. IRIDEX products are sold in the United States through a
direct sales force and internationally primarily through a network
of independent distributors into more than 100 countries. For
further information, visit the IRIDEX website at
http://www.iridex.com/
Safe Harbor Statement
This announcement contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Act of 1934, as amended,
including those statements concerning the Company’s strategic
priorities, market opportunity in Korea, marketing and launch
strategy, and plans to accelerate CYCLO G6 adoption and
utilization. These statements are not guarantees of future
performance and actual results may differ materially from those
described in these forward-looking statements as a result of a
number of factors, including the Company’s ability to execute on
its strategic goals and market adoption of its products. Please see
a detailed description of these and other risks contained in our
Annual Report on Form 10-K for the fiscal year ended December 30,
2017, and Quarterly Reports on Form 10-Q for subsequent fiscal
quarters, each of which was filed with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date and will not be updated.
Media Contact:Jamie Hall Pascale
Communications, LLC.724-417-0167jamie@pascalecommunications.com
Investor Relations Contact:Lynn Pieper Lewis or
Leigh Salvo(415) 937-5404investors@iridex.com
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Sep 2023 to Sep 2024